Electrodeposition of CuGaSe2 and CuGaS2 thin films for photovoltaic applications

The final publication is available at Springer via http://dx.doi.org/10.1007/s10008-016-3237-0.Abstract CuGaSe2 and CuGaS2 polycrystalline thin film absorbers were prepared by one-step electrodeposition from an aqueous electrolyte containing CuCl2, GaCl3 and H2SeO3. The pH of the solution was adjusted to 2.3 by adding HCl and KOH. Annealing improved crystallinity of CuGaSe2 and further annealing in sulphur atmosphere was required to obtain CuGaS2 layers. The morphology, topography, chemical composition and crystal structure of the deposited thin films were analysed by scanning electron microscopy, atomic force microscopy, energy dispersive spectroscopy and X-ray diffraction, respectively. X-Ray diffraction showed that the asdeposited CuGaSe2 film exhibited poor crystallinity, but which improved dramatically when the layers were annealed in forming gas atmosphere for 40 min. Subsequent sulphurization of CuGaSe2 films was performed at 400 °C for 10 min in presence of molecular sulphur and under forming gas atmosphere. The effect of sulphurization was the conversion of CuGaSe2 into CuGaS2. The formation of CuGaS2 thin films was evidenced by the shift observed in the X-ray diffraction pattern and by the blue shift of the optical bandgap. The bandgap of CuGaSe2 was found to be 1.66 eV, while for CuGaS2 it raised up to 2.2 eV. A broad intermediate absorption band associated to Cr and centred at 1.63 eV was observed in Cr-doped CuGaS2 films.This work was supported by Ministerio de Economia y Competitividad (ENE2013-46624-C4-4-R) and Generalitat Valenciana (Prometeus 2014/044). One of the authors (S. Ullah) acknowledges the European Union (IDEAS-Call-3, Innovation and Design for Euro-Asian scholars) for its financial support.Ullah, S.; Mollar García, MA.; Marí, B. (2016). Electrodeposition of CuGaSe2 and CuGaS2 thin films for photovoltaic applications. Journal of Solid State Electrochemistry. 20(8):2251-2257. https://doi.org/10.1007/s10008-016-3237-0S22512257208Calixto ME, Sebastian PJ, Bhattacharya RN, Noufi (1999) Sol Energ Mat Sol C 59:75–84Mandati S, Sarada BV, Dey SR, Joshi SV (2015) J Power Sources 273:149–157Jacobsson TJ, Fjällström V, Edoff M, Edvinsson T (2015) Sol Energ Mat Sol C 134:185–193Carrete A, Placidi M, Shavel A, Pérez Rodríguez A, Cabot A (2015) Phys Stat Sol (a) 212:67–71Saji VS, Ik-Ho C, Lee CW (2011) Sol Energy 86:2666–2678Park MG, Ahn SJ, Yun JH, Gwak J, Cho A, Ahn SK, Shin K, Nam D, Cheong H, Yoon K (2012) J Alloy Compd 513:68–74Saji VS, Lee SM, Lee CW (2011) J Korean Electrochem Soc 14:61–70Donglin X, Jangzhuang L, Man X, Xiujian Z (2008) J Non-Cryst Solids 354:1447–1450Araujo J, Ortíz R, López-Rivera A, Ortega JM, Montilla M, Alarcón D (2007) J Solid State Electroch 11(Issue 3):407–412Palacios P, Sanchez K, Conesa JC, Fernandez JJ, Wahnon P (2007) Phys Stat Sol A 203:1395–1401Palacios P, Sanchez K, Conesa JC, Wahnon P (2006) Thin Solid Films 515:6280–6284Lee H, Lee J-H, Hwang Y-H, Kim Y (2014) Curr Appl Phys 14:18–22Kim D, Kwon Y, Lee D, Yoon S, Lee S, Yoo B (2015) J Electrochem Soc 162:D36–D41Hou WW, Bob B, Li S, Yang Y (2009) Thin Solid Films 517:6853–6856Lee J, Lee W, Shrestha NK, Lee DY, Lim I, Kang SH, Nah YC, Lee SH, Yi W, Han SH (2014) Mater Chem Phys 144:49–54Yang JY, Lee D, Huh K, Jung SJ, Lee JW, Lee HC, Baek DH, Kim BJ, Kim D, Nam J, Kim GY, Jo W (2015) RSC Adv 5:40719–407257Sall T, Nafidi A, Marí B, Mollar M, Hartiti B, Fahoume M (2014) J Semicond 35:0630021–0630025Lee JH, Song WC, Yi JS, Joonyang K, Han WD, Hawang J (2003) Thin Solid Films 431-432:349–353Prabukanthan P, Dhanasekaran R (2007) Cryst Growth Des 7:618–623Guillemoles JF, Cowache P, Lusson A, Fezzaa K, Boisivon F, Vedel J, Lincot D (1996) J Appl Phys 79:7293–7302Aguilera I, Palacios P, Wahon P (2010) Sol Energ Mat Sol C 94:1903–1906Palacios P, Aguilera I, Wahnón P, Conesa JC (2008) J Phys Chem C 112:9525–952

Nutrition rehabilitation of undernourished children utilizing Spiruline and Misola

BACKGROUND: Malnutrition constitutes a public health problem throughout the world and particularly in developing countries. AIMS: The objective of the study is to assess the impact of an elementary integrator composed of Spiruline (Spirulina platensis) and Misola (millet, soja, peanut) produced at the Centre Medical St Camille (CMSC) of Ouagadougou, Burkina Faso, on the nutritional status of undernourished children. MATERIALS AND METHODS: 550 undernourished children of less than 5 years old were enrolled in this study, 455 showed severe marasma, 57 marasma of medium severity and 38 kwashiorkor plus marasma. We divided the children randomly into four groups: 170 were given Misola (731 ± 7 kcal/day), 170 were given Spiruline plus traditional meals (748 ± 6 kcal/day), 170 were given Spiruline plus Misola (767 ± 5 kcal/day). Forty children received only traditional meals (722 ± 8 kcal/day) and functioned as the control group. The duration of this study was eight weeks. RESULTS AND DISCUSSION: Anthropometrics and haematological parameters allowed us to appreciate both the nutritional and biological evolution of these children. The rehabilitation with Spiruline plus Misola (this association gave an energy intake of 767 ± 5 kcal/day with a protein assumption of 33.3 ± 1.2 g a day), both greater than Misola or Spiruline alone, seems to correct weight loss more quickly. CONCLUSION: Our results indicate that Misola, Spiruline plus traditional meals or Spiruline plus Misola are all a good food supplement for undernourished children, but the rehabilitation by Spiruline plus Misola seems synergically favour the nutrition rehabilitation better than the simple addition of protein and energy intake

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

: In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the World Health Organization prioritized the evaluation of treatment with convalescent plasma derived from patients who have recovered from the disease. We evaluated the safety and efficacy of convalescent plasma for the treatment of EVD in Guinea. : In this nonrandomized, comparative study, 99 patients of various ages (including pregnant women) with confirmed EVD received two consecutive transfusions of 200 to 250 ml of ABO-compatible convalescent plasma, with each unit of plasma obtained from a separate convalescent donor. The transfusions were initiated on the day of diagnosis or up to 2 days later. The level of neutralizing antibodies against Ebola virus in the plasma was unknown at the time of administration. The control group was 418 patients who had been treated at the same center during the previous 5 months. The primary outcome was the risk of death during the period from 3 to 16 days after diagnosis with adjustments for age and the baseline cycle-threshold value on polymerase-chain-reaction assay; patients who had died before day 3 were excluded. The clinically important difference was defined as an absolute reduction in mortality of 20 percentage points in the convalescent-plasma group as compared with the control group. : A total of 84 patients who were treated with plasma were included in the primary analysis. At baseline, the convalescent-plasma group had slightly higher cycle-threshold values and a shorter duration of symptoms than did the control group, along with a higher frequency of eye redness and difficulty in swallowing. From day 3 to day 16 after diagnosis, the risk of death was 31% in the convalescent-plasma group and 38% in the control group (risk difference, -7 percentage points; 95% confidence interval [CI], -18 to 4). The difference was reduced after adjustment for age and cycle-threshold value (adjusted risk difference, -3 percentage points; 95% CI, -13 to 8). No serious adverse reactions associated with the use of convalescent plasma were observed. : The transfusion of up to 500 ml of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed EVD was not associated with a significant improvement in survival. (Funded by the European Union's Horizon 2020 Research and Innovation Program and others; ClinicalTrials.gov number, NCT02342171.).<br/

GloPID-R report on Chikungunya, O'nyong-nyong and Mayaro virus, part I: Biological diagnostics

The GloPID-R (Global Research Collaboration for Infectious Disease Preparedness) Chikungunya (CHIKV), O'nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group is investigating the natural history, epidemiology and medical management of infection by these viruses, to identify knowledge gaps and to propose recommendations for direct future investigations and rectification measures. Here, we present the first report dedicated to diagnostic aspects of CHIKV, ONNV and MAYV. Regarding diagnosis of the disease at the acute phase, molecular assays previously described for the three viruses require further evaluation, standardized protocols and the availability of international standards representing the genetic diversity of the viruses. Detection of specific IgM would benefit from further investigations to clarify the extent of cross-reactivity among the three viruses, the sensitivity of the assays, and the possible interfering role of cryoglobulinaemia. Implementation of reference panels and external quality assessments for both molecular and serological assays is necessary. Regarding sero-epidemiological studies, there is no reported high-throughput assay that can distinguish among these different viruses in areas of potential co-circulation. New specific tools and/or improved standardized protocols are needed to enable large-scale epidemiological studies of public health relevance to be performed. Considering the high risk of future CHIKV, MAYV and ONNV outbreaks, the Working Group recommends that a major investigation should be initiated to fill the existing diagnostic gaps

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Genome sequencing reveals Zika virus diversity and spread in the Americas

Although the recent Zika virus (ZIKV) epidemic in the Americas and its link to birth defects have attracted a great deal of attention, much remains unknown about ZIKV disease epidemiology and ZIKV evolution, in part owing to a lack of genomic data. Here we address this gap in knowledge by using multiple sequencing approaches to generate 110 ZIKV genomes from clinical and mosquito samples from 10 countries and territories, greatly expanding the observed viral genetic diversity from this outbreak. We analysed the timing and patterns of introductions into distinct geographic regions; our phylogenetic evidence suggests rapid expansion of the outbreak in Brazil and multiple introductions of outbreak strains into Puerto Rico, Honduras, Colombia, other Caribbean islands, and the continental United States. We find that ZIKV circulated undetected in multiple regions for many months before the first locally transmitted cases were confirmed, highlighting the importance of surveillance of viral infections. We identify mutations with possible functional implications for ZIKV biology and pathogenesis, as well as those that might be relevant to the effectiveness of diagnostic tests

Epidemiological, clinical and developmental aspects of chronic kidney disease stages 3-5 (CRF) in children in a pediatric hospital in Senegal

Introduction: Our objective in this study was to describe both the epidemiological and clinical aspects and the difficulties of management of childhood CKD stages 3-5 in Senegal in order to express recommendations. Materials and Methods: This was a retrospective study from January 2005 to December 2013 in the pediatric ward of HALD. We included patients under 15years who have been showing for more than three months a glomerular filtration rate (GFR ) of less than 2 60ml/min/1.73 m calculated with the Schwartz formula. Results: We included in our study 53 cases during the study period, showing a p r e v a l e n c e o f 0 . 6 2 % o f hospitalisation. The average age of our patients was 10.6 years. Clinically, edema of renal type was present in 69.8 % of patients , proteinuria in 88.7 % of cases and arterial hypertension in 75.5 % of patients. Biologically , anemia was present in 100% of our patents. Classification of CKD showed that 71.7 % of cases were diagnosed at stage 5 of chronic kidney disease. The most common causal lesion we found consist ed of a cquir ed chronic glomerulopathy (52.8 %). Overall survival in children under hemodialysis for a period of 12 months was 34.3 %. Conclusion : The prevalence of CKD in children in our study was 0.62 %.. Managing such cases is a daily challenge for pediatricians and nephrologists. Hence the interest of building a pediatric nephrology unit.Keywords: Chronic kidney disease (chronic renal failure), Children, Glomerulopathy,Haemodialysis, Sénéga

Glomérulonéphrite lupique classe IV chez une jumelle de 15 ans au service de Pédiatre de l'Hôpital Aristide le Dantec de Dakar

No Abstrac

Long distance transport of irradiated male [i]Glossina palpalis gambiensis pupae[/i] and its impact on sterile male yield

[b]Background[/b]: The application of the sterile insect technique (SIT) requires mass-production of sterile males of good biological quality. The size of the project area will in most cases determine whether it is more cost effective to produce the sterile flies locally (and invest in a mass-rearing facility) or import the sterile flies from a mass-rearing facility that is located in another country. This study aimed at assessing the effect of long distance transport of sterile male [i]Glossina palpalis gambiensis pupae[/i] on adult male fly yield.[b]Methods[/b]: The male pupae were produced at the Centre International de Recherche-Developpement sur l'Elevage en zone Subhumide (CIRDES), Bobo-Dioulasso, Burkina Faso, and shipped with a commercial courier service in insulated transport boxes at a temperature of +/- 10 degrees C to Senegal (+/- 36 h of transport). Upon arrival in the insectary in Dakar, the pupae were transferred to an emergence room and the flies monitored for 3-6 days.[b]Results[/b]: The results showed that the used system of isothermal boxes that contained phase change material packs (S8) managed to keep the temperature at around 10 degrees C which prevented male fly emergence during transport. The emergence rate was significantly higher for pupae from batch 2 (chilled at 4 degrees C for one day in the source insectary before transport) than those from batch 1 (chilled at 4 degrees C for two days in the source insectary before transport) i.e. an average (+/- sd) of 76.1 +/- 13.2% and 72.2 +/- 14.3%, respectively with a small proportion emerging during transport (0.7 +/- 1.7% and 0.9 +/- 2.9%, respectively). Among the emerged flies, the percentage with deformed (not fully expanded) wings was significantly higher for flies from batch 1 (12.0 +/- 6.3%) than from batch 2 (10.7 +/- 7.5%). The amount of sterile males available for release as a proportion of the total pupae shipped was 65.8 +/- 13.3% and 61.7 +/- 14.7% for batch 1 and 2 pupae, respectively.[b]Conclusions[/b]: The results also showed that the temperature inside the parcel must be controlled around 10 degrees C with a maximal deviation of 3 degrees C to maximize the male yield